<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057663</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-09-03</org_study_id>
    <nct_id>NCT05057663</nct_id>
  </id_info>
  <brief_title>Intralesional Treatment of Plantar Wart</brief_title>
  <official_title>Intralesional Injection of Bleomycin Versus 5-fluorouracil in Treatment of Plantar Wart; a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Group 1; intralesional injection of bleomycin in plantar wart. Group 2; intralesional&#xD;
      injection of 5-fluorouracil in plantar wart&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to intralesional injection of bleomycin, 5fluorouracil in treatment of plantar wart</measure>
    <time_frame>3monthes</time_frame>
    <description>Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated&#xD;
Near Clear: A visible wart that is less than 3mm in maximal diameter (or length)&#xD;
A visible wart ≥ 3mm and &lt;6 mm in maximal diameter (or length)&#xD;
A visible wart ≥ 6mm in maximal diameter (or length)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Plantar Wart</condition>
  <arm_group>
    <arm_group_label>Bleomycin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Fluorouracil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin and 5-fluorouracil</intervention_name>
    <description>In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, &gt;10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.&#xD;
In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions</description>
    <arm_group_label>5-Fluorouracil group</arm_group_label>
    <arm_group_label>Bleomycin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to be considered for participation in this&#xD;
        study.&#xD;
&#xD;
          1. Subject is able to comprehend and is willing to sign an informed consent/assent for&#xD;
             participation in this study.&#xD;
&#xD;
          2. Male or female ≥ 8 years old.&#xD;
&#xD;
          3. Subject has a clinical diagnosis of common warts.&#xD;
&#xD;
          4. Subject has up to 1 Target Wart and up to 3 additional Non-Target Warts located on the&#xD;
             trunk or extremities. The identified Target and Non-Target Warts must meet the&#xD;
             requirements as defined below:&#xD;
&#xD;
               1. Each wart must have a longest axis that is ≥ 3mm and ≤ 8 mm and have a thickness&#xD;
                  of ≤3mm&#xD;
&#xD;
               2. Each wart must be a discrete lesion&#xD;
&#xD;
               3. Each wart must be present for at least 4 weeks&#xD;
&#xD;
               4. Not be covered with hair which, in the investigator's opinion, would interfere&#xD;
                  with the study medication treatment or the study evaluations&#xD;
&#xD;
               5. Not be in an intertriginous fold&#xD;
&#xD;
               6. Be the only common wart present when the circular cutout template is centered&#xD;
                  over the wart&#xD;
&#xD;
          5. The Target and Non-Target Warts must have a PWA ≥ 2.&#xD;
&#xD;
          6. Subject chemistry and complete blood count results are within normal limits. If any of&#xD;
             the laboratory values are outside normal range, the treating investigator must assess&#xD;
             the value/s as NOT clinically significant and document this in the subject's medical&#xD;
             chart in order for the subject to be eligible for randomization.&#xD;
&#xD;
          7. Woman of childbearing potential (WOCBP) must have a negative urine pregnancy test&#xD;
             within 14 days of the first application of study drug and agree to use an active&#xD;
             method of birth control for the duration of the study.&#xD;
&#xD;
          8. Subject is non-pregnant and non-lactating.&#xD;
&#xD;
          9. Subject is in good general health and free of any known disease state or physical&#xD;
             condition which, in the investigator's opinion, might impair the evaluation of any&#xD;
             Target or Non-Target Warts or which exposes the subject to an unacceptable risk by&#xD;
             study participation.&#xD;
&#xD;
         10. Subject is willing and able to follow all study instructions and to attend all study&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from this study if any 1 or more of the following criteria is met:&#xD;
&#xD;
          1. Subject has clinically atypical warts on the trunk or extremities.&#xD;
&#xD;
          2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic&#xD;
             immunodeficiency, transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rania Farouk, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag Faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rania Farouk, Resident</last_name>
    <phone>01283074271</phone>
    <email>rania_farouk_post@med.sohag.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sohag Faculty of Medicine</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Rania Farouk, resident</last_name>
      <phone>01283074271</phone>
      <email>rania_farouk_post@med.sohag.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Rania Farouk Daif</investigator_full_name>
    <investigator_title>Director, Head of Dermatology, Andrology and Venerology, Principal investigator, clinical professor</investigator_title>
  </responsible_party>
  <keyword>Intralesional Injection.</keyword>
  <keyword>Bleomycin.</keyword>
  <keyword>5-Fluorouracil.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Foot Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

